Emergent Biosolutions (EBS) Misses Q4 EPS by 1c; Issues Mixed Outlook
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.08 +5.39%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q4 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $94.6 million versus the consensus estimate of $95.09 million.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Deutsche Bank monitors UK auto sales as Chinese exports grow
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
